Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Korea Stock Exchange  >  SK Holdings Co., Ltd    A034730   KR7034730002

SK HOLDINGS CO., LTD

(A034730)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

SK Biopharmaceuticals prices at top of range for South Korea's biggest IPO in three years

share with twitter share with LinkedIn share with facebook
06/19/2020 | 04:48am EDT

Drugmaker SK Biopharmaceuticals Co Ltd priced its initial public offering on Friday at the top of its indicative range, aiming to raise 959 billion won ($794 million) in South Korea's biggest IPO in three years.

SK Biopharmaceuticals in November became the first South Korean company to receive U.S. Food and Drug Administration approval for an independently developed drug, called Xcopri, which is a treatment for epilepsy.

The drugmaker seeks to revive an IPO market hit by geopolitical concerns and fears of another outbreak of COVID-19.

SK Biopharmaceuticals' shares priced at 49,000 won, the top end of a range of 36,000-49,000 won per share indicated in a regulatory filing earlier this month.

The pricing values the company at 3.8 trillion won.

It will be the largest IPO in Seoul since Celltrion Healthcare raised 1 trillion won in its offering in July 2017.

SK Holdings Co Ltd will own 75% of the company after listing, expected on July 2.

(Reporting by Joyce Lee; Editing by Jan Harvey and Susan Fenton)

Stocks mentioned in the article
ChangeLast1st jan.
CELLTRION HEALTHCARE CO LTD End-of-day quote.
CELLTRION, INC. 1.39% 329000 End-of-day quote.81.77%
SK HOLDINGS CO., LTD 0.83% 242500 End-of-day quote.-7.44%
share with twitter share with LinkedIn share with facebook
Latest news on SK HOLDINGS CO., LTD
06/19SK Biopharmaceuticals prices at top of range for South Korea's biggest IPO in..
RE
06/04Malaysia's AirAsia considers fundraising, JV options to ride out pandemic
RE
05/21SK : life science Announces Results of Large, Open-Label, Long-Term Safety Study..
AQ
03/10SK Life Science Ready for U.S. Xcopri Launch After DEA Designation
DJ
2019SK China to set up $850 million fund with China's Hillhouse Capital - Korea E..
RE
2019SK : FDA Approves XCOPRI, an Anti-Epileptic Drug from SK Biopharmaceuticals and ..
AQ
2019South Korea's Aekyung, KCGI to join bidding for Asiana Airlines - sources
RE
2019Korean Air CEO Ousted From Board -- WSJ
DJ
2019Korean Air CEO Ousted From Board in Wake of 'Nut Rage,' Other Family Scandals
DJ
2019Asia's surging fuel exports depress refining industry profits
RE
More news
Financials
Sales 2020 85 724 B 71,1 B 71,1 B
Net income 2020 685 B 0,57 B 0,57 B
Net Debt 2020 37 163 B 30,8 B 30,8 B
P/E ratio 2020 24,6x
Yield 2020 2,18%
Capitalization 13 537 B 11 275 M 11 223 M
EV / Sales 2019
EV / Sales 2020 158x
Nbr of Employees 4 264
Free-Float 44,7%
Chart SK HOLDINGS CO., LTD
Duration : Period :
SK Holdings Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SK HOLDINGS CO., LTD
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Average target price 318 307,69 KRW
Last Close Price 242 500,00 KRW
Spread / Highest target 64,9%
Spread / Average Target 31,3%
Spread / Lowest Target -9,28%
EPS Revisions
Managers
NameTitle
Tae-Won Chey Co-Chief Executive Officer & Director
Dong-Hyun Jang President, Chief Executive Officer & Director
Jae-Ho Yeom Chairman
Eui-Dong Jang Executive Board Member & Head-Finance
Dae-Sik Cho Director
Sector and Competitors
1st jan.Capitalization (M$)
SK HOLDINGS CO., LTD-7.44%11 275
EXXON MOBIL CORPORATION-38.88%180 333
RELIANCE INDUSTRIES LTD27.80%158 635
BP PLC-37.10%74 012
CHINA PETROLEUM & CHEMICAL CORPORATION-27.08%67 600
PTT-14.77%34 889